Unraveling Lipoprotein Maturation and Transport Pathways in Gram-Negative Bacteria: Pioneering Targets for Innovative Antibacterial Therapies

The escalating challenge of antimicrobial resistance underscores the urgent need to identify novel targets for antibacterial drug development.

Despite the vast diversity of bacterial species, many remain poorly characterized, with significant gaps persisting in our understanding of their cellular mechanisms.

Addressing this knowledge deficit, our research focuses on elucidating the processes of acylation and lipoprotein transport in Gram-negative bacteria.

These molecular pathways are essential for bacterial survival, yet exhibit both conserved features and notable variations across species, offering potential targets for both broad-spectrum and targeted antibacterial therapeutics.

Given the low sequence similarities and divergent protein compositions among bacteria from different phyla and classes, it is plausible that these proteins interact with ligands with varying affinities.

Additionally, lipoprotein transport proteins have been implicated in binding lipid-based antibiotics, prompting our investigation into how analogous proteins from diverse phyla bind to a spectrum of linear and cyclic lipopeptides.

This systematic exploration aims to assess the potential of lipoprotein transport proteins as targets for novel antibacterial compounds. Ultimately, our research hold promise for the development of innovative treatments against microbial infections.